CDK13
protein-codingcyclin dependent kinase 13, the group of Cyclin dependent kinases
Gene summary
The protein encoded by this gene is a member of the cyclin-dependent serine/threonine protein kinase family. Members of this family are well known for their essential roles as master switches in cell cycle control. The exact function of this protein has not yet been determined, but it may play a role in mRNA processing and may be involved in regulation of hematopoiesis. Alternatively spliced transcript variants have been described.[provided by RefSeq, Dec 2009]
- CDC2L5
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~149.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0044302
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0044302
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0000508
Submitter: ClinGen
Variants in CDK13 were first reported in association with a syndromic condition in 2016 by Simfrim et al. (PMID: 27479907). This syndrome, characterized at the time by intellectual disability, congenital heart defects, and dysmorphic facial features, was reported by Simfrim et al. in seven subjects, all carrying de novo missense variants in the protein kinase domain of CDK13. One variant, p.Asn842Ser, is a recurrent variant, present in 4/7 subjects in this publication. **Summary of Case Level Data:** Variants in CDK13 (associated with similar phenotypes) have been reported in several other publications since the initial report of this syndromic constellation of features in 2016. While intellectual disability and developmental delay appears to be a universal feature, other phenotypes are only present in a subset of subjects, such as congenital heart malformations, autism, and gastrointestinal anomalies (among others). In total, 43 individuals have been reported across six publications, spanning from 2016-2018 (note, not all of these cases have been included in this curation, as definitive status was reached). All individuals are reported to have developmental disability or intellectual disability, along with impacts to additional body systems as described (i.e. a syndrome). Structural congenital heart defects have been reported in approximately 42% of affected individuals, with atrial septal defect and valve anomalies being the most commonly seen (PMID: 39971730). All currently reported variants lie in the protein kinase domain of CDK13, are missense, and de novo/suspected de novo (in a few cases where parental DNA was unavailable). Recurrent variants such as p.Asn842Ser further support the pathogenicity of these genetic changes, though this has not been evaluated through functional studies as of yet. The majority of cases for this curation were provided the default score for a missense de novo variant, 0.5. **Experimental Evidence:** Because of the recency of this syndrome being described, little experimental evidence exists to support the link between the gene and phenotype. One study from Novakova et al. (PMID: 31440507) in 2019 provided evidence that Cdk13 knock out mouse models showed a similar constellation of features to human heterozygotes. This included heart, brain, kidney, liver, and palate anomalies. These KO mice, homozygotes for null alleles in Cdk13, were incompatible with life; phenotypes were examined from embryos. While supporting the case-level evidence (in terms of the body systems impacted) this publication was not scored because it did not provide a reliable model for intellectual disability in humans (no behavioral assessments could be carried out, given embryonic lethality). Additionally, no human homozygotes have been observed. Future experimental studies and functional analyses will help clarify the role of CDK13 in human syndromic intellectual disability. In summary, at present there is ample case-level evidence to support a definitive classification for this gene-disease relationship. As more reports and studies become available, it will likely continue to support an association between CDK13 and syndromic ID, and further clarify the prevalence of different features of this syndrome (e.g. heart malformations, neurodevelopmental phenotypes, renal, gastrointestinal features, etc.)
Inheritance Pattern: AD
Disease ID:MONDO:0044302
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: The condition can involve congenital cardiac anomalies, and awareness may allow early management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CDK13 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_003718.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 258 | 9 | 269 | ||
| missense | 12 | 41 | 530 | 122 | 39 | 744 |
| nonsense | 13 | 17 | 14 | 44 | ||
| start loss | 1 | 1 | ||||
| frameshift | 17 | 17 | 22 | 56 | ||
| splice donor/acceptor (+/-2bp) | 3 | 8 | 11 | |||
| Total | 42 | 78 | 577 | 380 | 48 | 1125 |
Highest pathogenic variant AF is 0.000040263614
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_003709.3 | 14 | MANE Select | |
| Ensembl | ENSP00000181839.4 | 14 | MANE Select | |
| RefSeq | NP_112557.2 | 14 | Standard | |
| Ensembl | ENSP00000340557.5 | 14 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Neutrophil degranulation
- Gene expression (Transcription)
- Generic Transcription Pathway
- RNA Polymerase II Transcription
- Innate Immune System
Biological Process
- alternative mRNA splicing, via spliceosome
- transcription elongation from RNA polymerase II promoter
- protein phosphorylation
- regulation of mitotic nuclear division
- multicellular organism development
Molecular Function
- RNA binding
- protein kinase activity
- cyclin-dependent protein serine/threonine kinase activity
- protein binding
- ATP binding
Cellular Component
- cyclin-dependent protein kinase holoenzyme complex
- nuclear chromatin
- cyclin K-CDK13 complex
- extracellular region
- extracellular space
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000181839
- Coding exons
- 14
- Length
- 147098
- Individuals with no LoFs
- 125733
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 14
- Defined
- 125747
- p
- 0.0000557
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.35 | 510 | 683 | 0.747 | 0.0000357 | 9669 |
| Missense (PolyPhen) | 158 | 309.35 | 0.51075 | 3862 | ||
| Synonymous | -1.51 | 292 | 261 | 1.12 | 0.0000137 | 3100 |
| Loss of Function | 5.58 | 11 | 56.2 | 0.196 | 0.00000328 | 720 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.00020 | 0.00020 | rare |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000063 | 0.000062 | rare |
| South Asian | 0.000066 | 0.000065 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys- 51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef. {ECO:0000269|PubMed:16721827, ECO:0000269|PubMed:1731328, ECO:0000269|PubMed:18480452, ECO:0000269|PubMed:20952539}.;
- Disease
- DISEASE: Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD) [MIM:617360]: An autosomal dominant syndrome characterized by atrial and/or ventricular septal congenital heart defects, facial dysmorphism with hypertelorism, upslanted palpebral fissures, epicanthal folds, ptosis, strabismus, posteriorly rotated ears, thin upper lip, and small mouth. Patients manifest global developmental delay, delayed walking and speech acquisition, and intellectual disability. Some patients have mild microcephaly, a small cerebral cortex, and agenesis of corpus callosum. More variable features include clinodactyly and/or camptodactyly of the fingers, hypotonia, and joint hypermobility. {ECO:0000269|PubMed:27479907, ECO:0000269|PubMed:28807008}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.226
Intolerance Scores
- LoFtool
- 0.569
- RVIS EVS
- -1.08
- RVIS percentile EVS
- 7.28
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- S
- Essential (gene trap)
- K
- Indispensability pred.
- E
- Indispensability score
- 0.731
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |